pharma news today glp-1 obesity A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio 🧬 Could this be the

4.7 Pregnancy-related effects Although type 2 diabetes and obesity have been effectively treated with GLP-1 receptor agonists, their role in pregnancy and breastfeeding has been a controversial debate due to potential risks to the mothers health and fetal outcomes (87)

Therefore, women of childbearing age should be advised that significant weight loss may increase fertility, requiring effective contraception

Patients with type 2 diabetes in the SURPASS clinical trials lost between 12lb and 25lb on average

Inhibin, beta A regulates the transforming growth factor-beta pathway to promote malignant biological behaviour in colorectal cancer